Lvw Advisors, LLC Anebulo Pharmaceuticals, Inc. Transaction History

Lvw Advisors, LLC

$862 Million
Q2 2025

A detailed history of Lvw Advisors, LLC transactions in Anebulo Pharmaceuticals, Inc. stock. As of the latest transaction made, Lvw Advisors, LLC holds 349,617 shares of ANEB stock, worth $860,057. This represents 0.06% of its overall portfolio holdings.

Number of Shares

349,617

Previous 349,617 -0.0%

Holding current value

$860,057

Previous $485,000 3.71%

% of portfolio

0.06%

Previous 0.06%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 Apr 09, 2025	SELL	$1.02 - $2.04 $288,556 - $577,113	-282,899 Reduced 44.73%	349,617 $485,000
Q4 2024 Jan 16, 2025	SELL	$0.99 - $1.98 $8,437 - $16,875	-8,523 Reduced 1.33%	632,516 $1.06 Million
Q3 2024 Oct 09, 2024	SELL	$1.77 - $3.08 $1,770 - $3,080	-1,000 Reduced 0.16%	641,039 $1.24 Million
Q1 2024 Apr 17, 2024	SELL	$2.34 - $3.0 $2,340 - $3,000	-1,000 Reduced 0.16%	642,039 $1.84 Million
Q4 2023 Jan 12, 2024	SELL	$1.71 - $3.17 $50,089 - $92,855	-29,292 Reduced 4.36%	643,039 $1.56 Million
Q2 2023 Jul 14, 2023	SELL	$2.06 - $2.98 $2,060 - $2,980	-1,000 Reduced 0.15%	672,331 $1.58 Million
Q1 2023 May 02, 2023	SELL	$2.27 - $3.25 $1,323 - $1,894	-583 Reduced 0.09%	673,331 $1.95 Million
Q4 2022 Jan 18, 2023	SELL	$1.79 - $3.39 $1,879 - $3,559	-1,050 Reduced 0.16%	673,914 $0
Q3 2022 Oct 13, 2022	SELL	$2.8 - $5.49 $70,100 - $137,447	-25,036 Reduced 3.58%	674,964 $1.89 Million
Q2 2022 Jul 22, 2022	BUY	$2.7 - $7.15 $1.89 Million - $5.01 Million	700,000 New	700,000 $3.64 Million

Others Institutions Holding ANEB

# of Institutions

Shares Held

22.6M

Call Options Held

Put Options Held

View Full List

About Anebulo Pharmaceuticals, Inc.

Ticker ANEB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,633,200
Market Cap $63.1M
Description
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The ...

More about ANEB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Lvw Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Lvw Advisors, LLC with notifications on news.

Account